Valuation: Caplin Point Laboratories Limited

Market Cap 199B 2.09B 1.83B 1.68B 1.56B 2.96B 3.01B 20.16B 7.9B 97.81B 7.83B 7.66B 339B P/E 2026
17.9x
P/E 2027 * 27.9x
Enterprise Value 199B 2.09B 1.83B 1.68B 1.56B 2.96B 3.01B 20.16B 7.9B 97.81B 7.83B 7.66B 339B EV / Sales 2026
5.23x
EV / Sales 2027 * 8.01x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.15%
1 day-0.36%
1 week+2.91%
Current month-0.53%
1 month+13.10%
3 months+52.89%
6 months+44.84%
Current year+42.10%
1 week 2,501.6
Extreme 2501.6
2,689
1 month 2,291.1
Extreme 2291.1
2,689
Current year 1,500.3
Extreme 1500.3
2,689
1 year 1,500.3
Extreme 1500.3
2,689
3 years 801
Extreme 801
2,689
5 years 575
Extreme 575
2,689
10 years 176.2
Extreme 176.2
2,689
Manager TitleAgeSince
Chief Executive Officer 71 27/03/2015
Director of Finance/CFO - 18/02/2016
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 26/01/2010
Director/Board Member - 04/11/2025
Director/Board Member 71 27/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+2.91% - - 2.09B
-0.02%+1.69%+16.51%+85.36% 48.73B
+1.04%-1.33%+68.94%+115.21% 35.82B
+0.37%-0.87%-2.19%+42.18% 12.2B
-0.46%+1.17%+18.61%+98.42% 12.11B
+0.38%+1.75%+34.02%+123.93% 9.11B
-0.86%+0.17%+52.29%-3.73% 7.09B
-0.08%-0.91%+17.07%+44.58% 7B
+0.94%+3.40%+20.07%+244.40% 6.7B
-2.19%-3.38%-22.26%+7.68% 5.78B
Average -0.20%-0.29%+22.56%+84.22% 16.06B
Weighted average by Cap. +0.05%+0.29%+29.60%+90.56%

Financials

2026 2027 *
Net sales 21.28B 223M 195M 180M 166M 316M 321M 2.15B 844M 10.45B 837M 819M 36.2B 24.88B 261M 228M 210M 195M 369M 375M 2.52B 987M 12.22B 979M 957M 42.32B
Net income 6.16B 64.56M 56.47M 52.08M 48.19M 91.46M 92.99M 624M 244M 3.03B 242M 237M 10.48B 7.13B 74.67M 65.32M 60.24M 55.74M 106M 108M 721M 283M 3.5B 280M 274M 12.12B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
10/07/26 2,615.00 -0.24% 87,952
09/07/26 ₹2,621.40 +3.68% 119,270
08/07/26 ₹2,528.40 -1.50% 111,612
07/07/26 ₹2,566.80 -2.19% 100,780
06/07/26 ₹2,624.20 +3.39% 187,621
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,620.40INR
Average target price
2,505.00INR
Spread / Average Target
-4.40%

Quarterly revenue - Rate of surprise